Novo Nordisk is launching a cheaper authorised version of its blockbuster diabetes drug Ozempic in South Africa, intensifying its fight against unregulated compounded medicines, lower-cost generics and Eli Lilly’s fast-growing Mounjaro.
Browsing: Ozempic
Johannesburg: Novo Nordisk will launch a more affordable authorised copy of its Ozempic diabetes drug in South Africa later this month, partnering with healthcare company Acino to expand patient access.